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CORRESPONDENCE
Mastitis and Human Immunodeficiency Virus
Transmission: Chemokines and Maternal Monocytes
To the Editor—Semba et al. [1] linked inflammatory processes
in the lactating breast with the risk of transmission of human
immunodeficiency virus (HIV) [1]. Although this is a compelling
set of data, we should like to draw attention to three difficulties
with the study.
First, the study would have been considerably stronger had
a milk cell count or bacterial count—the reference standards
for mastitis—been done. A significant component of the HIV
load is located in the cellular fraction of milk, particularly in
monocyte/macrophage cells, although this proportion changes
with phases of lactation and probably with mastitis too [2].
This virus burden does not appear to have been estimated by
use of the techniques described. Milk contains chemokines and
cytokines, which also increase in mastitis and alter cell acti-
vation status in the mother’s breast and the neonatal intestine.
To describe infectivity in mastitis, it therefore becomes critical
to estimate the contribution of increased cell-bound intracel-
lular virus and free virus together with the effects of increased
cytokines and chemokines that may alter the neonatal defenses
[3, 4]. There may be protective effects of milk to prevent neona-
tal infection by HIV; these will not be detected if only some of
the data relating to infection or inflammation are collected.
Second, the use of milk sodium levels makes it difficult to
determine with precision cases of mastitis, because this measure
increases nonspecifically in hand-expressed milk samples, as
used in this study. Sodium concentration also changes in in-
dividual mothers, depending on their stages of lactation [5].
The use of 12 mmol/L as a cutoff appears to have been made
on a statistical basis without prior studies of the Malawian
population under review or the sample collection system used
in the study. Other clinical data have shown that many healthy
mothers have sodium concentrations 112 mmol/L with normal
potassium levels, normal cell counts, and no evidence of mas-
titis [5]. Thus, although there appears to be an association of
raised sodium levels with HIV transmission, it is not clear
whether this is due to mastitis.
Finally, Semba et al. [1] described the use of antibiotics to
treat mastitis, suggesting that the data do not relate to breast
engorgement but to a truly infective bacterial condition in one-
third of Malawian mothers. This rate is considerably higher
than that observed in the United Kingdom or The Gambia,
where !3% of lactating mothers receive antibiotics for mastitis.
Is this a feature of malnutrition in the Malawian population,
such as lower vitamin A levels, for instance? Published mastitis
rates vary extensively, and none is derived from a large pro-
spective study relevant to a developing country. Mastitis is rec-
ognized as being most common at the beginning and end of
lactation and is relatively rare in midlactation, yet the mothers
were reviewed at this point in lactation. It is also unclear
whether all mothers with mastitis transmitted their infection to
their infants. If so, the rate of ∼30% transmission by breast-
feeding is higher than those cited elsewhere, particularly in re-
cent studies from South Africa [6].
The association proposed by Semba et al. [1] is important to
investigate further, as it will probably be relevant to the vertical
transmission of human T cell lymphotropic virus types 1 and
2—and perhaps also to cytomegalovirus, Epstein-Barr virus,
and human herpesvirus 7—and therefore will be important to
significant numbers of mothers worldwide. A genetic predis-
position to mastitis, observed in all mammals, needs to be de-
fined, as do associations between chemokine genotypes and this
route of infection. The role of inflammation in promoting trans-
placental retroviral infection has been investigated more thor-
oughly, and clinical data are available. By contrast, mastitis or
breast inflammation in nursing mothers merits considerably
more attention.
Colin A. Michie1 and William Lynn2
Departments of 1Pediatrics and 2Infectious Diseases, Ealing Hospital
NHS Trust, London, United Kingdom
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Reply
To the Editor—We agree with Michie and Lynn [1] that there
are further unanswered questions regarding the nature of mas-
titis and vertical transmission of human immunodeficiency vi-
rus (HIV) in developing countries. Knowledge in this area is
advancing rapidly. Mastitis is a common and neglected problem
of breast-feeding women [2]. Our study in Malawi provides
JID 2000;181 (February) Correspondence 801
some early insight into mastitis, HIV load in breast milk, and
vertical transmission. Because we used archived breast milk
samples to assess mastitis in our study, we did not perform
leukocyte counts or cultures [3]. We noted the need for further
investigation of the microbiology and treatment of mastitis
in developing countries. Cell-free HIV load was measured in
breast milk, and the measurement of cell-associated HIV in
human milk remains to be elucidated in the laboratory. Elevated
breast milk sodium : potassium ratios and elevated sodium con-
centrations are associated with elevations of inflammatory and
immunologic mediators in breast milk, including lysozyme,
lactoferrin, secretory leukocyte protease inhibitor, transforming
growth factor b-2, interleukin-8, and RANTES [4–7], all sug-
gesting the presence of inflammation.
Breast milk sodium concentrations are high in colostrum,
during mastitis, and at the termination of weaning. Milk so-
dium concentrations can also be elevated with breast engorge-
ment and during lactation failure with a poorly feeding infant.
Careful, nontraumatic collection of hand-expressed milk sam-
ples does not result in nonspecific elevation of breast milk so-
dium, and the attribution of elevated breast milk sodium to
milk collection methods practiced in recent studies is inconsis-
tent with the available chemokine and cytokine data [4–7]. The
use of 12 mmol/L as a cutoff for sodium concentrations in
breast milk was 3 SD above the mean for human milk sodium
as measured by ion-selective electrodes [3]. It should be noted
that, in the older literature, higher breast milk sodium concen-
trations have been reported when atomic absorption spectros-
copy and related methods were used, and caution is needed
when comparing studies and milk sodium values that have been
obtained by use of different laboratory techniques.
The incidence rates of mastitis from the older literature are
underestimated, because earlier studies tended to estimate the
incidence of mastitis on the basis of clinic visits [2]. The prev-
alence of mastitis among women in Malawi at 6 weeks post-
partum, as assessed by elevated breast milk sodium concentra-
tions, is consistent with recent studies of mastitis from
developing countries such as Bangladesh [4], Tanzania [5], and
South Africa [8]. In addition, recent longitudinal studies in the
United States, Finland, and Australia suggest that clinically
apparent mastitis occurs in 20%–33% of breast-feeding women
[2]. The highest incidence of mastitis is observed in the first
several weeks postpartum [2, 4, 5, 8]. Our study in Malawi
assessed mastitis at 6 weeks postpartum during the period of
the highest known incidence of mastitis. The proportion of
mothers with mastitis who transmitted HIV to their infants was
clearly shown in table 2 [3]. Between ages 6 weeks and 12
months, as shown in table 2, the overall rate of HIV trans-
mission through breast-feeding in this study was ∼5%, not 30%,
and this rate is consistent with other studies conducted in the
same study population [9].
As suggested by Michie and Lynn [1], the association between
mastitis and transmission of HIV, as shown in Malawi [3], has
relevance for vertical transmission of other viruses and merits
attention. Other studies have also demonstrated that mastitis
is a risk factor for vertical transmission of HIV in Kenya and
South Africa [8, 10]. Mastitis, as indicated by elevated sodi-
um : potassium ratio, is associated with elevated HIV load in
breast milk and is primarily a unilateral process [8]. Evidence
is accumulating that mastitis may be a key risk factor for HIV
transmission through breast milk, and it is potentially amenable
to treatment and prevention [2, 5].
Richard D. Semba
Johns Hopkins University School of Medicine, Baltimore, Maryland
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Preliminary Falsification of EIA Screening Is
Cost-Effective in the Two-Step Serodiagnosis
of Lyme Disease
To the Editor—We read with great interest the article by Trevejo
et al. [1] that described a simplified procedure for the laboratory
diagnosis of Lyme disease (LD). The authors assumed as “cer-
tain” the clinical diagnosis of LD and on this basis calculated
the sensitivity of 3 different diagnostic approaches. We suggest
that there is some bias in the assumption that 25 EIA-positive
serum samples plus 2 more Western immunoblot (WB)–con-
firmed samples, among equivocal results, sum up to a sensitivity
of 41%, by the authors’ simplified method, in the early phase
of LD. Similarly, the assumption was made that 39 EIA-positive
sera, with no WB confirmation of equivocal results, give a
sensitivity of 71% in the convalescent phase. The authors ignore
that 6 (22%) of 27 and 23 (59%) of 39 EIA-positive results were
disproved by WB. We cannot understand what scientific rea-
soning allows the omission of the WB-unconfirmed, EIA-equiv-
ocal results and the inclusion of WB-unconfirmed but EIA-
positive cases.
As far as we know, the “etiologic certainty” of a given in-
fection can be determined only by the isolation of a causative
organism, which is difficult to do for LD. At present, the best
available parameter of relative certainty seems to be WB confir-
mation, on the basis of which the sensitivity of other diagnostic
approaches should be calculated. It is possible, of course, for
the scientific community to decide that a physician-diagnosed
erythema migrans rash >5 cm is the most sensitive determi-
nation of early LD. If so, a further simplified and cost-effective
approach would be not to do any EIA screening.
The discrepancies between the screening tests and WB con-
firmation indicate that in the serodiagnosis of LD a major
problem is specificity, since some unrelated disease conditions
other than spirochetes and flagellated bacterial infections in-
terfere with the results [2]. This is of great concern for the
diagnosis of patients with symptoms compatible with late LD
who live in geographic areas in which LD is not known to be
endemic. We were very surprised that Trevejo et al. [1] reported
an EIA-screening specificity of 97%, which we believe was likely
due to use of a small control group.
In a setting of unknown endemicity for LD, we carried out
a large case-control study with subgroups including healthy and
sick subjects. Tests with the same commercial polyvalent EIA
(Vidas; BioMe´rieux Vitek, Hazelwood, MO) used by Trevejo
et al. [1] resulted in negative findings for 167 (88%) of 189
subjects. Only 2 (9%) of 22 positive or equivocal EIAs were
confirmed by Western blot. Major sources of interference in-
cluded acute phase and asymptomatic infectious mononucleosis
(specificity, 78%) and polyclonal hypergammaglobulinemia
(specificity, 87.5%) [3]. Recently, in various acute infections of
viral or bacterial etiology, we found a specificity of 78%. When
we included the results for our case patients, 21 serum samples
were unequivocally WB negative whereas 40 were either EIA
positive (19 samples) or EIA equivocal (21 samples) (EIA vs.
WB specificity, 47.5%). In the series presented by Trevejo et al.
[1], the specificity of EIA versus WB was 75% in the early LD
serum specimens but only 37% in the convalescent samples. In
our experience, 22.5% of positive/equivocal EIA results were
due to Epstein-Barr virus (EBV) viral capsid antigen (VCA)
IgM interference. Thus, in view of the low (or perhaps absent)
endemicity in our setting, we decided to routinely falsify pos-
itive/equivocal EIA tests with EBV VCA IgM, to reduce the
waste of resources. Immunoblot confirmation was done only
on specimens for which falsification failed. If the suspicion of
LD is high, we suggest that WB should be postponed until the
interfering factor is cleared, if this is possible; if it is not, an
immunoblot, however performed, can be interpreted with the
knowledge that an interfering factor is present. When possible,
polymerase chain reaction using biologic fluids could provide
a further interpretative key [4].
In our country the cost per specimen of the approach rec-
ommended by the Centers for Disease Control and Prevention,
calculated for reagents only, is $84.70; the cost per specimen
of the falsification approach is $9.12. Until better-standardized
and less cross-reactive reagents are marketed [5, 6], the falsi-
fication approach (by EBV IgM in our study but perhaps by
other approaches in different settings) allows cost savings and,
most importantly, avoids laborious immunoblots—the results
of which often cannot be interpreted—and, at least in part,
misdiagnosis of LD.
Maria Adriana Piras and Antonio Aceti
Institute of Infectious Diseases, University of Sassari, Sassari, Italy
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Reply
To the Editor—Piras and Aceti [1] point out some current lim-
itations of Lyme disease (LD) diagnosis and associated labo-
ratory serology—specifically, the uncertainty of serology in the
absence of culture confirmation [2]. Although culture confir-
mation remains the reference standard for the diagnosis of LD,
it is not typically used in a clinical setting.
Our study evaluated several serologic testing approaches
among a patient population with a high pretest likelihood of
infection with LD, based on residence in an area highly endemic
for LD and the presence of a physician-diagnosed erythema
migrans rash >5 cm in diameter [3]. We agree that the simplest
and least costly approach for a patient with a physician-diag-
nosed erythema migrans rash and endemic exposure is “treat,
don’t test.” However, in primary care practice, many persons
with this presentation are tested.
Comparative evaluation of serologic testing approaches
among our study population demonstrated that the use of West-
ern immunoblotting only as an arbiter of equivocal results from
EIA tests of serum samples was more sensitive and less costly
than the CDC-recommended approach of applying Western
blot (WB) to EIA-positive as well as EIA-equivocal samples
[4]. All approaches were highly specific and were based on test-
ing of geographic controls (selected from an area highly en-
demic for LD, as were the patients) who did not have a history
of LD or recent symptoms suggestive of LD. The question of
cross-reactivity has been studied by others [5] and was not an
objective of our study.
We continue to support the use of the CDC-recommended
2-test approach for the serodiagnosis of LD [4], because of the
all-too-common practice of performing serologic testing for LD
on patients with a low pretest probability of LD. For those
patients with a low likelihood of LD, the utility of following
EIA-positive results with WB has been demonstrated [5, 6].
Rosalie T. Trevejo,1 Martin E. Schriefer,2
and David T. Dennis2
1Epidemiology Program, School of Public Health, University
of California, Berkeley; 2Centers for Disease Control and Prevention,
Fort Collins, Colorado
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TT Virus: Evidence for Transplacental Transmission
To the Editor—Epidemiology and pathogenic properties of the
recently described TT virus (TTV) are under intensive scrutiny.
There is little doubt that TTV is transmitted through blood
and blood products, as shown by the high prevalence rates we
and others have observed in polytransfused persons [1–3]. For
example, in 660 persons tested by nested polymerase chain re-
action (PCR), we found no specific pathologies that correlated
with enhanced infection rates except in polytransfused hemo-
philiacs, who were 73% TTV positive versus 50% for the overall
group [1]. Furthermore, by use of a real time PCR assay, which
permits an accurate quantitative evaluation of viremia and a
very efficient detection of TTV DNA, hemophiliacs exhibited
the highest TTV loads when compared with healthy subjects
and other patient groups (authors’ unpublished data). On the
other hand, there is also no doubt that the spread of TTV
infection in the general population is much too great to be
explained solely on the basis of transmission through blood.
Indeed, prevalence rates of up to 90% have been observed,
although extreme variation has been reported depending on
geographic origin and, possibly of more importance, on the
sensitivity of the detection method used [1, 3–5]. This has led
to a search for additional routes of transmission. Thus, the
demonstration that TTV is shed in stool suggests an important
role for the orofecal route [6].
Evidence has also been sought for mother-to-child trans-
mission. In a recent letter, Simmonds et al. [7] reported that all
tested newborns aged 0–3 months were TTV-DNA negative [7].
Because 75% of children aged 3 months to 1 year were TTV
positive, Simmonds et al. concluded that the infection is not
acquired in utero but occurs early in postnatal life, possibly
from environmental sources. However, our evidence differs. By
using real time PCR as the detection method, we found TTV
in the serum of 15 of 18 Italian mothers tested and in 12 of
paired cord sera. Of importance, the virus loads in the cord
were in the same range as those in the mothers (table 1), thus
excluding the possibility that cord blood had been contami-
nated with maternal blood during collection and suggesting that
TTV had entered the fetus well before delivery. The reasons for
804 Correspondence JID 2000;181 (February)
Table 1. Presence and loads of TTV DNA in paired sets of maternal
and cord sera, as determined by a sensitive real time polymerase chain
reaction (PCR) assay.
Serum









1 2 ! 5 3 102 2 ! 5 3 102
2 2 ! 5 3 102 2 ! 5 3 102
3 2 ! 5 3 102 2 ! 5 3 102
4 1 4.8 3 106 2 ! 5 3 102
5 1 1.9 3 104 2 ! 5 3 102
6 1 1.0 3 104 2 ! 5 3 102
7 1 9.5 3 105 1 9.6 3 103
8 1 5.5 3 104 1 4.3 3 103
9 1 1.4 3 104 1 2.5 3 104
10 1 1.1 3 104 1 3.0 3 103
11 1 1.1 3 104 1 1.5 3 104
12 1 7.0 3 103 1 1.1 3 104
13 1 1.4 3 104 1 1.9 3 104
14 1 9.8 3 103 1 1.3 3 104
15 1 2.6 3 104 1 8.6 3 103
16 1 1.2 3 104 1 6.0 3 103
17 1 1.7 3 104 1 1.3 3 104
18 1 8.0 3 104 1 2.0 3 104
NOTE. Lower limit of sensitivity of PCR, DNA copies/mL; dy-25.0 3 10
namic range, >5 logs; interassay reproducibility, within 0.6 log. All maternal and
cord sera were tested simultaneously in triplicate at least twice.
a Informed consent was obtained from all mothers.
b Positive samples were confirmed by amplification and sequencing of 175-bp
fragment in open reading frame 1 of the TTV genome (nt 2281–2455).
the difference between our results and those of Simmonds et
al. are unclear. It is possible that the exquisite sensitivity of our
real time PCR permitted the demonstration of TTV levels that
would have escaped detection by other methods. Alternatively,
it is possible that, similar to observations for the human pap-
illomaviruses and other viruses, variants or subspecies of TTV
exist that present important biologic and epidemiologic differ-
ences. In any case, our data support the concept that TTV can
cross the placenta and that transmission in utero is an important
means of TTV diffusion.
Antonietta Morrica,1 Fabrizio Maggi,1
Maria Linda Vatteroni,1 Claudia Fornai,1
Mauro Pistello,1 Pietro Ciccorossi,2 Elio Grassi,3
Andrea Gennazzani,4 and Mauro Bendinelli1
1Virology Section and Retrovirus Center, Department of Biomedicine,
2I Medical Clinic–Gastroenterology Unit, 3U.O. Obstetrics
and Gynecology, Azienda USL 12-Versilia, and 4Department
of Reproductive Medicine, University of Pisa, Pisa, Italy
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Neglected Opportunities
To the Editor—How would the press, politicians, and funding
agencies react to evidence that a new vaccination strategy re-
duced human immunodeficiency virus (HIV) transmission by
75%, required only a single priming dose and no boosters, was
expected to be active against diverse HIV strains, and could be
made available immediately at minimal cost? We would expect
a flurry of press attention and editorial comment and calls for
an emergency program to implement the strategy in the shortest
possible time.
Such a report was recently published by Lavreys et al. [1],
but the “vaccination strategy” was not an injection but male
circumcision. In this prospective cohort study, uncircumcised
status was an independent risk factor for HIV transmission
(hazard rate ratio, 4.0) in a multivariate analysis that controlled
for confounding demographic and behavioral factors. However,
this important and well-designed study, which overcame major
limitations of previous studies, has thus far sparked little notice.
In this it is similar to previous studies of circumcision and
transmission of HIV/sexually transmitted disease, most of
which, although less rigorously controlled and mostly retro-
spective, reached similar conclusions.
Lavreys et al. [1] convincingly argue that the accumulated
epidemiologic evidence and the biologic plausibility are strong
enough to justify implementation of the strategy now, pending
more data on acceptability. For those who remain unconvinced,
a randomized controlled trial of adult circumcision is entirely
feasible and could be rapidly undertaken by skeptics.
It is worth asking, however, why this promising strategy has
been investigated at such a leisurely pace (as pointed out by
Lavreys et al., 150 years and counting) and why, even now, it
has failed to capture the imagination or enthusiasm of more
than a handful of investigators. Understanding the factors that
JID 2000;181 (February) Correspondence 805




(male/female)Male Female Male Female
White 1.90 0.88 2.14 0.22 9.73
Black 12.36 3.48 0.47 0.17 2.76
Ratio 0.15 0.25 4.55 1.29
NOTE. Incidence rates are per 100,000 person-years and are age standard-
ized to the world population. SEER is the Surveillance, Epidemiology, and End
Results Program of the National Cancer Institute of the United States.
have obstructed attention to this potential opportunity may
allow us to develop this and other inadequately explored pre-
ventive options more effectively in the future.
Possible explanations include the low-tech and decidedly
nonnovel nature of the intervention; distaste for the procedure;
the momentum of a decades-long swing of pediatrician and
parent opinion away from circumcision as a painful procedure
with insufficient documented medical benefits; a perceived in-
consistency in the promotion or even the study of male cir-
cumcision, while decrying female “circumcision” (actually cli-
torectomy); the false assumption that implementation would
necessarily require neonatal circumcision and, thus, would take
decades to accrue a benefit; and the unproven assumption that
attitudes toward circumcision are immutable consequences of
religion and culture. Neglecting pursuit of this opportunity on
the basis of any of these reasons is unscientific and regrettable.
HIV-prevention efforts have been largely directed toward
promotion of condoms and the search for a vaccine. After
nearly 2 decades, a vaccine still appears to be far off, and,
although condoms are an important tool for HIV prevention,
the epidemic has nonetheless continued its steady expansion.
The enormous benefits of a vaccine, should one prove feasible,
and the proven efficacy of condoms, when people are willing
to use them, should not blind us to opportunities to explore
and implement alternative means of HIV prevention.
Thomas R. Moench
ReProtect, LLC, Baltimore, Maryland
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Helicobacter pylori, Lifestyle Risk Factors,
and Adenocarcinoma of the Esophagus
To the Editor—We read with interest the article by Blaser [1],
in which a compelling argument is made to link the continuing
decline in Helicobacter pylori infection rates to increases in gas-
troesophageal reflux disease, Barrett’s esophagus, and esoph-
ageal adenocarcinoma. The hypothesis is consistent with data
indicating lower adenocarcinoma rates, despite higher squa-
mous rates, among US blacks (table 1) [2] and the report of
significantly higher H. pylori infection rates in blacks (70%)
than in whites (34%) in an asymptomatic US population [3].
Alternative explanations for lower adenocarcinoma rates in
blacks, such as lower consumption of alcohol and tobacco
products or lower prevalence of obesity, a factor associated with
increased risk of adenocarcinoma [4], are less plausible, given
substantially higher rates for squamous cell carcinoma of the
esophagus in blacks and similar levels of obesity in the two
populations [5].
Although the accumulating evidence suggests that H. pylori
is protective against esophageal adenocarcinoma, data in table
1 indicate that this is only part of the picture. The male/female
adenocarcinoma rate ratios (whites, 9.73; blacks, 2.76) are
higher than the white/black rate ratios (males, 4.55; females,
1.29), despite similar H. pylori infection rates in men and
women [3]. Thus, although lower H. pylori infection rates may
explain higher adenocarcinoma rates in whites, they cannot
explain substantially higher rates in men.
The etiology of esophageal adenocarcinoma remains to be
explained. The existing evidence suggests that obesity [4] and
gastroesophageal reflux disease [6] may be important risk fac-
tors. The prevalence of obesity has increased in line with esoph-
ageal adenocarcinoma rates over the past few decades and now
exceeds 50% in many North American and European popu-
lations [5]. In addition, alcohol and tobacco are established risk
factors for squamous cell carcinoma of the esophagus and may
help to explain substantially higher male adenocarcinoma rates.
Although infection with H. pylori may significantly reduce the
risk of esophageal adenocarcinoma, an excess risk is likely to
persist in those with predisposing lifestyle risk factors, such as
overweight persons who smoke. Due consideration of these risk
factors is clearly warranted.
Roger N. Maric and Kar K. Cheng
Department of Public Health and Epidemiology,
University of Birmingham, Birmingham, United Kingdom
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Reply
To the Editor—Maric and Cheng [1] make important points
about the epidemiology of adenocarcinoma of the esophagus
by comparing rates among US blacks and whites and among
males and females. Essentially all diseases have multifactorial
causes; the challenge is to identify those characteristics that are
associated with the highest risk of disease development. Over
the past 25 years, adenocarcinoma of the esophagus has been
rapidly increasing among persons in developing countries [2].
When disease rates change rapidly, environmental factors usu-
ally play the critical role. The fact that the increase in esoph-
ageal adenocarcinomas is disproportionate in different ethnic
groups and among men, compared with that among women,
implies differential exposure to the offending factor(s). As
Maric and Cheng indicate, differences in body mass index are
clearly one part of the puzzle.
The rates for many diseases differ substantially for men and
women. Despite nearly similar rates of exposure to Helicobacter
pylori, duodenal ulcer rates are 2–4-fold higher among men
than among women, a differential that cannot be entirely ex-
plained by known risk factors such as smoking. For noncardia
gastric cancer, another disease associated with H. pylori, rates
among men also are substantially greater than those among
women [3]. However, analysis of incidence data indicates that
rates among both men and women rise appreciably with age;
the age at which the big increase begins in women is shifted
∼10 years later than that for men, and the slopes of the 2 curves
after the 10-year shift are nearly identical [4]. Thus, the differ-
ential in disease rates can be largely explained by a protective
factor that women have for ∼10 years longer than men. A
similar phenomenon has been observed for atherosclerotic heart
disease (ASHD), and most evidence suggests that female hor-
mones are involved in the protective effect. ASHD rates in-
crease substantially among women after menopause, in essence
paralleling trends among men. The rise in esophageal adeno-
carcinomas is relatively recent, and the numbers are not yet
large; however, in the future, analysis of age-specific rates by
sex may be useful.
Regardless of these considerations, it now has become clear
that gastroesophageal reflux disease (GERD) is the most im-
portant risk factor for the development of esophageal adeno-
carcinoma [5] and that GERD is becoming more prevalent [6].
It is critically important to identify the triggers for this
phenomenon; my hypothesis is that the lack of cag1 H.
pylori strains (which I term “acagia”) is a major risk factor
for development of Barrett’s esophagus and subsequent
adenocarcinoma.
Martin J. Blaser
Division of Infectious Diseases, Vanderbilt University School
of Medicine, Nashville, Tennessee
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Reemergence of Invasive Haemophilus influenzae
Type b Disease in Alaska: Is It Because
of Vaccination with Polyribosylribitol Phosphate
Outer Membrane Protein Complex (PRP-OMPC)
or Failure to Vaccinate with PRP-OMPC?
To the Editor—We read with interest the article by Galil et al.
[1] on the reemergence of invasive Haemophilus influenzae type
b (Hib) disease in a well-vaccinated population in remote
Alaska. The authors describe a dramatic decline in cases of
invasive Hib disease among Alaska Natives following near-
exclusive vaccination with the Hib conjugate vaccine poly-
ribosylribitol phosphate outer membrane protein complex
JID 2000;181 (February) Correspondence 807
(PRP-OMPC; Merck, West Point, PA), from January 1991 until
December 1995. Following a change in Hib vaccine regimen
to DTP-HbOC (diphtheria and tetanus toxoids and pertussis
vaccine adsorbed and Hib conjugate vaccine [diphtheria
CRM197 protein conjugate]; American Home Products, Pearl
River, NY), in January 1996, 10 cases of invasive disease were
reported during the next 12 months, prompting a 15-day cross-
sectional study of oropharyngeal Hib carriage in children aged
1–5 years during the spring of 1997. The intensity of Hib car-
riage (e.g., the number of colonies per plate) was not quantified.
Galil et al. conclude that “cases of invasive disease increased,
suggesting on-going Hib transmission despite widespread
vaccination. . . . Widespread vaccination with PRP-OMP[C] Hib
conjugate vaccine did not eliminate carriage in this population”
[1, p. 101]. We have a number of concerns about the authors’
interpretation of their results.
Pharyngeal colonization with Hib, its role in disease trans-
mission, and the effect of vaccination on colonization remain
poorly understood. Barbour [2] found Hib carriage in 8% of
children 4 years after vaccination with HbOC, compared with
5% in unvaccinated children. Among Hib carriers, an inverse
relationship between Hib colony count and anti-PRP concen-
tration was found: all vaccinated Hib carriers had very low Hib
colony counts. In another study, Barbour et al. [3] noted that
both the mechanism and the duration of conjugate vaccine
inhibition of Hib colonization are uncertain. Hall et al. [4] stud-
ied Hib carriage in Alaska Natives in 1982–1983 and found a
colonization level of 6.8% despite historically very high rates
of invasive Hib disease. They concluded that “mechanisms for
increased exposure which would not be reflected in high car-
riage rates may exist for these young children” [4, p. 1190].
Furthermore, the Galil study found no differences in the prev-
alence of colonization between villages with and without recent
cases of invasive Hib disease that would explain the outbreak
cases.
A potential misinterpretation of the study would be that the
elimination of Hib carriage is primarily dependent on the choice
of Hib vaccine. As Galil et al. [1] suggest, other factors may
have contributed to continuing Hib carriage in this population
of Alaska Natives.
Never-vaccinated children, older than the population studied
by Galil et al., are recognized as a source of nasopharyngeal
Hib carriage [5]. Although 97% of the population surveyed had
received >3 doses of a Hib conjugate vaccine, no vaccine cov-
erage information was available for children in the remaining
46 villages. Given that a convenience sample was used, it is
likely that the villages chosen for the carriage survey also were
more receptive to vaccination campaigns.
If age-appropriate Hib vaccination coverage were variable
or if older never-vaccinated children were found to carry Hib,
sources of Hib transmission could persist. In an environment
of incomplete coverage, it would be impossible to definitively
assess the impact of Hib vaccination on Hib carriage, because
pockets of unvaccinated children could serve as reservoirs for
reintroducing the organism. These populations may have served
as the source of Hib transmission to young infants susceptible
by virtue of vaccination with DTP-HbOC, the “unmasking ef-
fect” described by the authors.
PRP-OMPC is highly effective. In Israel, the efficacy and
effectiveness of the vaccine were 98.7% and 94.9%, respectively,
and cases of disease in infants !3 months old (prior to the age
when one can expect a direct protective effect of vaccine)
dropped sharply, consistent with vaccine-induced reduction in
pharyngeal Hib carriage (herd immunity) [6]. Among the Nav-
ajo in the southwestern United States, a population similar in
Hib disease incidence and risk factors to the Alaska Natives,
PRP-OMPC had 195% efficacy against invasive disease in in-
fants aged 2–18 months after 2 doses of vaccine [7].
Although the study by Barbour et al. [3] demonstrated per-
sistent pharyngeal Hib carriage following vaccination with
HbOC, several studies have documented a reduction in Hib
carriage levels following vaccination with Hib conjugate vac-
cines [8–10]. However, he effect of Hib conjugate vaccines on
carriage may vary substantially among populations with high
and low rates of invasive Hib disease incidence [11]. The study
by Galil et al. was conducted in a population that experienced
one of the highest reported incidence rates of invasive Hib
disease in the prevaccine era [12]. The only other published
study on the effect of any Hib conjugate vaccine on carriage
in a population with a high incidence of invasive Hib disease
found that pharyngeal carriage in a Navajo population vac-
cinated with PRP-OMPC decreased from 4.8% to 2.3% [13].
The report by Galil et al. [1] underscores the need for further
investigation of the role of pharyngeal colonization in the trans-
mission of invasive Hib disease as well as of the effect of Hib
vaccination on carriage. We agree that early seroprotection,
high levels of vaccine coverage, and continued disease surveil-
lance are crucial to attaining the goal of invasive Hib disease
eradication.
Jennifer M. Dargan, Paul M. Coplan,
Karen M. Kaplan, and Alexander Nikas
Merck Research Laboratories, Merck & Co., Inc.,
West Point, Pennsylvania
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Reply
To the Editor—We thank Dargan et al. [1] for their interest in
our recent report of the reemergence of invasive Haemophilus
influenzae type b (Hib) disease in rural Alaska Native infants.
We appreciate their support for the key messages of our study,
specifically the need for early protection in this population, high
levels of vaccination coverage, continued surveillance for in-
vasive Hib disease, and further investigation of the epidemi-
ology of pharyngeal colonization, including the effect of Hib
vaccination on carriage. The results of this study were instru-
mental in reestablishing polyribosylribitol phosphate Neisseria
meningitidis outer membrane protein (PRP-OMP) vaccine as
the Hib conjugate vaccine for the first dose of the Hib vacci-
nation program in Alaska. The resumption of the use of PRP-
OMP for the first dose has led to a return to lower rates of
infant Hib disease in rural Alaska Natives, an indication of the
unique immunologic features of this vaccine.
As Dargan et al. [1] note, our knowledge of the effect of Hib
conjugate vaccination on colonization is incomplete, and the
relationship between colonization and disease transmission re-
mains unclear; however, we will clarify several points raised by
their letter. The study of the effect of PRP-OMP vaccine on
colonization in the Navajo population is not the only study of
the effect of Hib vaccination on colonization in a high-incidence
population [2]. Adegbola et al. [3], in a randomized, controlled
trial of the impact of PRP–tetanus toxoid Hib conjugate vaccine
on oropharyngeal carriage in The Gambia, found a 60% re-
duction in the prevalence of carriage (11.0% among unvacci-
nated children vs. 4.4% among fully vaccinated children). In
addition, persistent Hib carriage has been documented in Aus-
tralian Aboriginal children, despite routine vaccination with
PRP-OMP vaccine; this population also experienced a high
incidence of Hib disease and an epidemiologic pattern similar
to that observed in rural Alaska Natives [4]. Dargan et al. note
that the study by Barbour et al. [5] showed no difference in
Hib colonization 4 years after immunization with H. influenzae
oligosaccharide-CRM197 (HbOC) [5]. However, this study in-
cluded just 60 infants who had received HbOC in an immu-
nogenicity trial 4 years earlier and were living in a general
population of unimmunized children, not a setting in which
herd immunity would be expected. The more pertinent com-
parison is with studies of Hib colonization following wide-
spread vaccination of the entire population. These studies con-
vincingly document a substantial reduction in Hib colonization
and provide the basis for understanding the herd immunity that
occurs following widespread immunization [6–8].
Dargan et al. [1] accurately point out that the contribution
of Hib colonization in older children and adults to transmission
is poorly understood. The influence of vaccination coverage
rates and the regimen and vaccine used is likewise unclear. We
should clarify that infants in rural Alaska are routinely vac-
cinated during well-child care visits and itinerant public health
nurse visits, not through vaccination campaigns, as Dargan et
al. suggest, and that immunization coverage levels in Alaska,
including rural Alaska Native populations, are as high as, or
higher than, the national average. In general, by 2 years of age
190% of Alaska Native children, including those in the villages
in our study, have received >3 doses of Hib conjugate vaccines.
Therefore, low vaccination coverage rates are not likely to ex-
plain our observations.
Further research into the factors that contribute to the elim-
ination of Hib colonization in various populations is urgently
needed. At this time, the role of factors such as carriage in older
age groups, the intensity of colonization and transmission, the
vaccination schedule, and the vaccine used in Alaska is not
clearly elucidated. We agree that it would be a misinterpretation
of the results of this study to suggest that we would not have
observed continued colonization had another Hib conjugate
vaccine been used. To address the remaining questions, we have
initiated several other studies that we hope will clarify the
relative importance of these various factors and lead to im-
proved strategies for elimination of Hib disease in Alaska and
elsewhere.
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Mortality in Serologically Unconfirmed
Mediterranean Spotted Fever
To the Editor—I read with interest the article by Paddock et
al. [1], who described the detection of occult mortality due to
Rocky Mountain spotted fever (RMSF) by demonstrating
Rickettsia rickettsii antigens or DNA in blood and tissues [1].
In Mediterranean countries, including Israel, spotted fever is
caused by members of the R. conorii complex, which are an-
tigenically related to R. rickettsii. The clinical course of Med-
iterranean spotted fever (MSF), however, is milder than that
of RMSF, especially in children, and the fatality rate is con-
sidered to be !5% [2]. In 1993, Wolach and I [3] reported fatal
MSF in 3 Israeli children who had presented with a febrile
disease lasting 5–7 days, septic shock, mental changes, hypon-
atremia, and bleeding tendency. A rash, macular or purpuric,
was present in 2 children and absent in the third. A presumptive
diagnosis of meningococcemia or sepsis of unknown origin was
entertained. The 3 children were empirically treated with b-
lactam antibiotics and aggressive supportive therapy but died
within 24 h of admission. The diagnosis of MSF was confirmed
in 2 patients by cell culture and by animal inoculation in the
third. Antibodies to spotted fever–group rickettsiae, as deter-
mined by microimmunofluorescence, were negative in 2 chil-
dren, whereas a borderline titer of 1 : 80 was found in 1.
Early administration of specific therapy with tetracyclines or
chloramphenicol significantly decreases mortality due to rick-
ettsial infections [4]. Institution of such therapy, however, re-
quires that the rickettsial etiology of the illness be suspected
on clinical and/or epidemiologic grounds, because these anti-
microbial drugs are not usually given empirically to febrile pa-
tients. In addition, pediatricians frequently hesitate to start
therapy with tetracycline in febrile young children without a
definitive proof of a rickettsial diagnosis, because of the po-
tential risk of teeth staining. Usually the diagnosis of rickett-
sioses relies on serologic tests, whereas culture of the organism
and polymerase chain reaction methods are not routinely used
or universally available. The series of patients reported by Pad-
dock et al. [1] and our 3 patients clearly show that serologic
tests may be unreliable for diagnosing or excluding rickettsial
infections, especially in persons presenting with fulminant dis-
ease. Had specific isolation techniques for rickettsiae not been
attempted, the diagnosis would have been missed in our 3 pa-
tients, and their deaths would have been attributed to infections
caused by unidentified pathogens. Thus, it appears that, when
alternative methods for confirming the disease are not used,
the diagnosis of MSF may be missed by serology, resulting in
underestimation of the true case/fatality rate of the infection.
Because MSF may follow an unpredictable, rapid fatal course
similar to that of RMSF, it seems prudent to advise prompt
administration of empirical tetracycline therapy whenever the
diagnosis is suspected.
Pablo Yagupsky
Clinical Microbiology Laboratory, Soroka Medical Center,
Ben-Gurion University of the Negev, Beer-Sheva, Israel
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Reply
To the Editor—We appreciate the comments by Yagupsky [1],
which underscore several of the salient features of spotted fe-
ver–group rickettsial infections that we emphasized in our re-
port [2]. For patients, diagnosticians, and clinicians faced with
the potentially tragic consequences of Rocky Mountain spotted
fever or severe Mediterranean spotted fever (MSF), these points
merit repeating. First, the nonspecific signs and symptoms early
in the course of rickettsial infections mimic many other infec-
tious and noninfectious syndromes. Second, the diagnostic chal-
lenges posed by these diseases are compounded by the lack of
rapid and widely available confirmatory tests early in the course
of the illnesses. Finally, spotted fevers have the potential to kill
otherwise healthy persons in !1 week after onset of symptoms,
emphasizing the need for early administration of appropriate
therapy.
The immunohistochemical (IHC) test described in our report
uses an antibody that reacts with multiple spotted fever–group
rickettsiae, including members of the Rickettsia conorii complex
that causes MSF. In this context, we have used this assay to
diagnose previously unexplained fatal illnesses caused by spot-
ted fever–group rickettsiae other than R. rickettsii. Our expe-
rience reinforces the comments of Yagupsky [1] and includes
confirmation of fatal spotted fever infections in 2 adult Israeli
patients for whom serologic evidence of MSF was lacking. The
first patient was a 31-year-old woman who died 6 days after
onset of an illness characterized by fever, myalgias, headache,
and respiratory insufficiency. The second patient was a 38-year-
old man who died 7 days after being hospitalized for fever and
vomiting. Both patients developed thrombocytopenia and pe-
techial or purpuric rashes over the course of their illnesses.
Similar to 2 of the pediatric patients described in the earlier
report by Yagupsky and Wolach [3], neither of these 2 patients
demonstrated diagnostic levels of antibody reactive with spot-
ted fever–group rickettsiae when serum samples were tested by
use of an indirect immunofluorescence assay. However, tissues
from both patients obtained at autopsy demonstrated micro-
scopic lesions consistent with histopathologic findings of fatal
MSF [4], and IHC staining for spotted fever–group rickettsiae
revealed abundant rickettsial antigens and intact rickettsiae in
and around blood vessels and within reticuloendothelial cells
(figure 1).
We agree with Yagupsky’s recommendation to administer
tetracycline antimicrobials (preferably doxycycline) to children
of any age when spotted fever–group rickettsioses are consid-
ered in the differential diagnosis. The recognized propensity of
tetracyclines to bind to dental enamel should not dissuade phy-
sicians from using the most effective drug for the treatment of
these potentially life-threatening infections. The decision to use
doxycycline in young children is never made casually, and the
rationale for this choice of therapy should be discussed with
the child’s parents [5]. However, it should be recognized that a
single short course (i.e., 5–7 days) of doxycycline should not
result in cosmetically significant staining of teeth [6, 7]. For
patients with Rocky Mountain spotted fever or severe MSF,
there is a relatively narrow window of time during which ef-
fective antibiotic therapy dramatically reduces the risk of death
[8]. Since laboratory tests available to most physicians do not
assist in early diagnosis, initiation of therapy should be based
on clinical, and especially epidemiologic, findings (e.g., unex-
plained febrile illness associated with known tick bite or tick
exposure or unexplained fever with thrombocytopenia, rash, or
headache occurring during spring or summer months in an area
where the disease is endemic).
Isolation of R. conorii from patients’ blood and tissues con-
firmed the diagnosis of spotted fever for each of the 3 pediatric
patients described by Yagupsky and Wolach [3] and reflects the
clinical acumen of these investigators. Although isolation is the
reference standard for diagnosis, culture is seldom attempted
during the acute phase of illness, even when a rickettsial in-
fection is suspected, and cannot be performed retrospectively
on autopsy specimens unless samples were appropriately col-
lected and stored (e.g., frozen at 2707C). Biosafety level 3 prac-
tices and facilities are recommended if culture of spotted fe-
ver–group rickettsiae is attempted [9]. In contrast, IHC testing
provides a method for retrospective confirmatory diagnosis on
archived samples months or even years after the illness. In this
context, IHC is a versatile technique that can help resolve prob-
lematic issues relating to the diagnosis of otherwise unexplained
illnesses and provide new insights into the clinical course and
epidemiologic features of these diseases [10].
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Figure 1. Immunohistochemical localization of spotted fever–group rickettsial antigens in tissues of patients with fatal spotted fever, by
immunoalkaline phosphatase stain with naphthol phosphate–fast red substrate and hematoxylin counterstain. A, Rickettsiae and rickettsial antigens
associated with damaged endothelium in myocardial interstitium (patient 1); original magnification, 3158. B, Abundant rickettsial antigens within
denuded intravascular endothelial cells in small vessel in kidney (patient 1); original magnification, 3100. C, Rickettsial nodule in cerebral cortex
(patient 1); original magnification, 3158. D, Spotted fever–group rickettsiae and rickettsial antigens in cytoplasms of Kupffer cells in liver (patient
2); original magnification, 3158.
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Oropharyngeal Candida Colonization and Human
Immunodeficiency Virus Type 1 Infection
To the Editor—Gottfredsson et al. [1], in a cross-sectional study
of oropharyngeal Candida colonization in 83 patients with hu-
man immunodeficiency virus type 1 (HIV-1) infection, reported
that only plasma HIV-1 load was predictive of Candida load;
neither CD4 lymphocyte level nor use of antiretroviral therapy
was associated with colonization [1]. They hypothesized that
high levels of HIV-1 may suppress local mucosal immune re-
sponses, thereby permitting increased Candida colonization,
and speculated that control of HIV-1 replication may restore
local immune function. Their findings certainly are consistent
with these possibilities. However, there are at least 2 alternative
explanations that might account for the interesting findings.
Cross-sectional studies do not provide information about
causality for any associations found. However, even if high
levels of HIV-1 do cause increased Candida colonization, sup-
pressed local mucosal immunity is not the only possible mech-
anism that might explain such an occurrence. It was recently
shown in vitro that HIV-1 glycoproteins may promote the vir-
ulence of Candida albicans [2]. Thus, increased local HIV-1
replication might have a direct effect on increased Candida colo-
nization, without necessarily requiring the presence of defects
in local immune function. Furthermore, such a mechanism need
not imply disassociation of HIV-1 effects on local mucosal im-
munity from those on CD4 lymphocyte counts, as would be
suggested by a better correlation of Candida colonization with
HIV-1 effects on local immune function than with effects on
CD4 lymphocyte counts.
In addition, patient self-report is known to overestimate ad-
herence to prescribed medications [3], especially for regimens
requiring multiple doses daily [4]. Preliminary observations of
HIV-infected current and former drug users in the Bronx, New
York, showed that medication adherence assessed by electronic
monitoring was significantly correlated with HIV load but that
self-reported adherence was not [5]. HIV-1 load is inversely
correlated with actual use of effective highly active protease
inhibitor–containing antiretroviral regimens. Even though oro-
pharyngeal Candida colonization was not independently as-
sociated with the reported use of protease inhibitors, its asso-
ciation with HIV-1 load suggests that there may well have been
less use of protease inhibitors in colonized patients. Since pro-
tease inhibitors have anticandidal activity [6], it is possible that
the actual use of protease inhibitors, better reflected by low
HIV-1 load than by self-reported adherence, had a direct effect
on reducing oropharyngeal Candida colonization. It would be
of interest to know if the independent association of Candida
colonization with HIV-1 load was seen in the subgroup of pa-
tients known not to have received either current or recent pro-
tease inhibitor therapy.
Until longitudinal studies are available and actual rather than
reported use of chemotherapeutic agents with antifungal activ-
ity can be accurately measured and controlled for in analyses,
it may be premature to conclude that HIV-1 load has a direct
effect on local mucosal immunity, which promotes orophar-
yngeal Candida colonization.
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Reply
To the Editor—We thank Klein et al. [1] for their cogent re-
sponse to our work [2] in which we reported that, among var-
ious clinical parameters in a cohort of human immunodefi-
ciency virus (HIV)–infected patients, plasma HIV RNA levels
had the most significant association with oropharyngeal Can-
dida colonization. As Klein et al. point out, this association
could be the result of 3 possibilities: HIV affecting mucosal
JID 2000;181 (February) Correspondence 813
immunity, HIV affecting the Candida species directly, or a direct
effect of protease inhibitor (PI) therapy on Candida species. In
our report, we speculated that the first of these 3 possibilities
was the most likely explanation for our observations. Although
we agree with Klein et al. that the other 2 possibilities should
be considered, we believe fewer data support these hypotheses.
The possibility that HIV has a direct effect on Candida species
is provocative, and we referenced 2 studies that described the
interaction of HIV glycoproteins inhibiting phagocytosis and
intracellular killing of Candida in vitro [3, 4]. We interpreted
these studies as supporting our hypothesis that HIV has an
adverse effect on local mucosal immunity. To our knowledge,
there is no convincing evidence in the literature to support the
notion that HIV can increase the virulence of Candida species
in vivo.
Finally, the possibility of PIs having an anticandidal effect
is intriguing. In a study by Cassone et al. [5], which Klein et
al. [1] reference, the PIs ritonavir and indinavir both appeared
to have an anticandidal effect in a rat vaginal candidiasis model.
Unfortunately, this work was unavailable to us during the prep-
aration of our manuscript. If we assume that the anticandidal
effect of PIs is significant enough to decrease oropharyngeal
colonization, then it certainly seems as if the association be-
tween low levels of Candida colonization and low viral load
measurements can be attributed in part to PI exposure. How-
ever, in our cohort of patients, we did not find that the self-
reported use of PIs was associated with candidal colonization.
In our report, we referenced a study showing that antiretroviral
monotherapy with reverse-transcriptase inhibitors resulted in a
significant reduction in oropharyngeal candidiasis [6], thus giv-
ing support to the idea that improvements in local immunity
may be more important than the direct effect of PIs on yeast.
Furthermore, our anecdotal experience in the clinic has shown
that patients with azole-resistant thrush can have resolution of
symptoms by initiation of PI-sparing highly active antiretro-
viral regimens. We also have seen patients known to be com-
pliant with PI therapy, as determined by measurement of blood
levels, who have high viral load measurements and thrush. All
these observations cause us to be cautious in assigning any
direct antifungal effect to PIs.
We agree with Klein et al. [1] that it is premature to conclude
that our observations of low Candida colonization correlating
with low viral load measurements reflect improved mucosal
immunity. It was, and remains, our intention to provide a work-
ing hypothesis to explain our findings, and we hope to further
support this hypothesis through ongoing prospective studies.
Magnus Gottfredsson, Gary M. Cox,
and John R. Perfect
Department of Medicine, Duke University
Medical Center, Durham, North Carolina
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